Jiangsu Hengrui Medicine Co., Ltd.

Shanghai Stock Exchange 600276.SS

Jiangsu Hengrui Medicine Co., Ltd. EBIT Margin for the year ending December 31, 2023: 20.80%

Jiangsu Hengrui Medicine Co., Ltd. EBIT Margin is 20.80% for the year ending December 31, 2023, a 9.56% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Jiangsu Hengrui Medicine Co., Ltd. EBIT Margin for the year ending December 31, 2022 was 18.98%, a 9.77% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. EBIT Margin for the year ending December 31, 2021 was 17.29%, a -30.50% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. EBIT Margin for the year ending December 31, 2020 was 24.89%, a -3.97% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. EBIT Margin for the year ending December 31, 2019 was 25.92%, a 0.18% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

Shanghai Stock Exchange: 600276.SS

Jiangsu Hengrui Medicine Co., Ltd.

CEO	Mr. Hong Bin Dai
IPO Date	Oct. 18, 2000
Location	China
Headquarters	38 Huanghe Rd Eco & Tech Dev Park
Employees	19,611
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.

Key trends

Past 5 years